Oh lawd... I'm being pulled back in.... Iovance Biotherapeutics (IOVA,Financial) has maintained a Buy rating from H.C. Wainwright, which reiterated a $20 price target for the stock. This comes after the company released retrospective data on its commercial drug, Amtagvi. The results highlight substantial clinical responses, notably among patients in earlier treatment stages. Out of 41 patients assessed at four different authorized centers, the drug demonstrated a physician-assessed objective response rate of 48.8%. This indicates that Amtagvi is performing as expected, and even surpassing forecasts for patients who have undergone fewer prior treatments.
update: .81 cents-----------> $15 Seres Therapeutics, Inc.(MCRB) 15.27 +2.70 (+21.44%) As of 11:20:03 AM EDT. Market Open.
They are playing games I have a $4.01 limit order in they moved it on me. Not filled Buy 1500 IMMUNEERING CORP CLASS A COM (IMRX) $4.01 Limit
I'm not going to get hit on IMRX. Not in the mood to play games today. I was within 1 cent... arrrrrrg
How to Grow Lemon Trees: The Complete Guide Botanical Name Citrus limon Plant Type Fruit Sun Exposure Full Sun Soil pH Slightly Acidic to Neutral Bloom Time Spring Flower Color White Hardiness Zone 9 10 11
NasdaqGS - Nasdaq Real Time Price•USD Nebius Group N.V.(NBIS) 51.37 +7.07 (+15.96%)<----------------------------- As of 2:32:23 PM EDT. Market Open. Goldman Sachs Thinks Nebius Stock Can Rally 50% From Here.